Accreditation, Access, and Outcomes: What Real-World CAR-T Data Tells Us

Debra Patt and Tara Graff open this Insights series by examining why CAR T-cell therapy access remains geographically concentrated, drawing parallels to earlier waves of specialized cancer treatment adoption.

Dr. Graff details how rural geography and unfavorable payer reimbursement compound to limit which community oncology practices can safely and sustainably offer T-cell engaging therapies.

Dr. Porter frames access as CAR T-cell therapy's central challenge, outlining the safety, efficacy, and affordability gains still needed before outpatient administration can meaningfully close the gap for patients.

The panel traces FACT accreditation's origins in transplant medicine and asks whether a decade of improved CRS and neurotoxicity management has outpaced the original rationale for its strict requirements.